Nav: Home

New cell models for ocular drug discovery

December 04, 2019

Researchers at the University of Eastern Finland have developed two new cell models that can open up new avenues for ocular drug discovery. The new cell models are continuously growing retinal pigment epithelial cells, which have many benefits over the models currently used by researchers and pharmaceutical companies. The models were developed by Professor Arto Urtti's Ocular Drug Delivery group at the University of Eastern Finland.

The retinal pigment epithelium is located in the back of the eye, forming the outer blood-retinal barrier. Pigment epithelial cells play a key role in, e.g., age-related macular degeneration, which makes them an interesting target for drug therapy. The retinal pigment epithelium also regulates the access of drugs from the blood stream into the eye and vice versa, further highlighting the importance of this cell type for drug discovery.

Up until now, cultivated retinal pigment epithelial cell lines have lacked both pigmentation and the blood-retinal barrier, which has complicated their use.

Cells can be fed with pigment that binds drugs

The retinal pigment epithelium (RPE) is characterised by strong pigmentation. Many drugs bind to cellular pigment and, consequently, can accumulate in RPE cells. The new cell model makes it possible to study this accumulation in greater detail than before.

In the new model, non-pigmented RPE cells can be re-pigmented by feeding them with melanin pigment.

"Re-pigmentation is possible, thanks to the naturally active phagocytosis, or cellular eating, of RPE cells. Instead of just using pigment, we used melanosomes, i.e. live pigmented cell organelles, to re-pigment the cells. Our research group has already previously developed a method to isolate live melanosomes. In this study, we showed that the host cell accepts the transferred melanosomes and doesn't destroy them," Postdoctoral Researcher Mika Reinisalo from the University of Eastern Finland says.

Published in Scientific Reports, the study also described the uptake of different drugs in melanosomes. According to the researchers, most drugs that bind to melanin at high levels were taken up by the melanosomes, whereas the same was true only for a small number of drugs that bind to melanin at low levels.

"By using non-pigmented cells as controls, we were able to study how much of a drug given to the cells eventually ends up in the melanosomes. Next, we need to find out for how long the melanosomes can hold on to a drug, and whether this causes any harm. The accumulation of drugs in the melanosomes can, on the other hand, make it possible to target drugs at specific tissues," Reinisalo notes.

New cell model forms a more realistic blood-retinal barrier

Retinal pigment epithelial cells also form the blood-retinal barrier that protects the eye from circulating xenobiotics. For drug therapy, the blood-retinal barrier is crucial, as it regulates both the entry and exit of drugs to and from the eye. In earlier cell models, the epithelial layer isn't thick enough, allowing drugs to pass through it too quickly. This paints an erroneous picture of how drugs get transported into the patient's eye.

Earlier this year, the same research group published a study in Pharmaceuticals, presenting a new RPE cell population that had spontaneously arisen from the RPE cell line. This population forms a tight epithelial layer, resembling the real-life epithelial layer of the eye.

"We named this cell population after its discoverer, Senior Laboratory Technician Lea Pirskanen, who is also one of the authors of the study. These cells are now known as LEPI cells. We decided to study them in more detail and discovered that in comparison to earlier cell models, LEPI cells are better differentiated and they form a tighter and more realistic barrier through which drugs have to pass," Postdoctoral Researcher Laura Hellinen from the University of Eastern Finland says.

Both cell models are useful for ocular drug discovery and they also reduce the need for animal testing.
-end-
The studies were funded by the Academy of Finland and the Finnish Cultural Foundation.

For further information, please contact: Postdoctoral Researcher Mika Reinisalo, University of Eastern Finland, mika.reinisalo@uef.fi

Ocular Drug Delivery Research Group at the University of Eastern Finland: https://www.uef.fi/en/web/odd

Research articles:

Hellinen Laura, Hagström Marja, Knuutila Heidi, Ruponen Marika, Urtti Arto and Reinisalo Mika. Characterization of artificially re-pigmented ARPE-19 retinal pigment epithelial cell model. Scientific Reports, vol. 9, Article number: 13761 (2019). https://www.nature.com/articles/s41598-019-50324-8

Hellinen Laura, Pirskanen Lea, Tengvall-Unadike Unni, Urtti Arto and Reinisalo Mika. Retinal pigment epithelial cell line with fast differentiation and improved barrier properties. Pharmaceutics 2019, 11(8), 412. https://doi.org/10.3390/pharmaceutics11080412

University of Eastern Finland

Related Drug Discovery Articles:

An open-access tool to accelerate drug discovery
The Chemical Checker provides processed, harmonized and ready-to-use bioactivity information on more than 1M small molecules.
New macrolactone database could aid drug discovery, research
Researchers have created a free-to-use database of 14,000 known macrolactones -- large molecules used in drug development -- which contains information about the molecular characteristics, chemical diversity and biological activities of this structural class.
Discovery of a drug to rescue winter depression-like behavior
A group of animal biologists and chemists at the Institute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, has used a chemical genomics approach to explore the underlying mechanism of winter depression-like behavior and identified a drug that rescues winter depression-like behavior in medaka fish.
Fat-fighting drug discovery
Cancer-fighting compound fights obesity and diabetes.
New cell models for ocular drug discovery
Researchers at the University of Eastern Finland have developed two new cell models that can open up new avenues for ocular drug discovery.
Machine learning's next frontier: Epigenetic drug discovery
Scientists at Sanford Burnham Prebys Medical Discovery Institute have developed a machine-learning algorithm that gleans information from microscope images -- allowing for high-throughput epigenetic drug screens that could unlock new treatments for cancer, heart disease, mental illness and more.
Discovery of how colorectal cancer drug works will help more patients
Some colorectal cancer patients with a certain gene mutation benefit from a chemotherapy drug called cetuximab, although the mechanism of how this drug worked was unknown.
Speeding up the drug discovery process to help patients
An international research team is perfecting a method to predict the potential clinical implications of new drugs before clinical trials even start.
Bioluminescence sensors make new approaches to drug discovery possible
Canadian and Brazilian researchers describe the use of 13 molecular tools for measuring different intracellular signaling pathways and evaluating the action mechanisms of new drugs.
Light-based production of drug-discovery molecules
EPFL chemists have developed a light-based chemical method for cheap and simple production of chemical molecules used in drug discovery, such as muscle relaxants and antimicrobials.
More Drug Discovery News and Drug Discovery Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Meditations on Loneliness
Original broadcast date: April 24, 2020. We're a social species now living in isolation. But loneliness was a problem well before this era of social distancing. This hour, TED speakers explore how we can live and make peace with loneliness. Guests on the show include author and illustrator Jonny Sun, psychologist Susan Pinker, architect Grace Kim, and writer Suleika Jaouad.
Now Playing: Science for the People

#565 The Great Wide Indoors
We're all spending a bit more time indoors this summer than we probably figured. But did you ever stop to think about why the places we live and work as designed the way they are? And how they could be designed better? We're talking with Emily Anthes about her new book "The Great Indoors: The Surprising Science of how Buildings Shape our Behavior, Health and Happiness".
Now Playing: Radiolab

The Third. A TED Talk.
Jad gives a TED talk about his life as a journalist and how Radiolab has evolved over the years. Here's how TED described it:How do you end a story? Host of Radiolab Jad Abumrad tells how his search for an answer led him home to the mountains of Tennessee, where he met an unexpected teacher: Dolly Parton.Jad Nicholas Abumrad is a Lebanese-American radio host, composer and producer. He is the founder of the syndicated public radio program Radiolab, which is broadcast on over 600 radio stations nationwide and is downloaded more than 120 million times a year as a podcast. He also created More Perfect, a podcast that tells the stories behind the Supreme Court's most famous decisions. And most recently, Dolly Parton's America, a nine-episode podcast exploring the life and times of the iconic country music star. Abumrad has received three Peabody Awards and was named a MacArthur Fellow in 2011.